Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma

BACKGROUND: Glioblastoma (GBM) is a very frequent primary tumour in the cerebrospinal nervous system. Temozolomide (TMZ) is the first-line treatment for patients with GBM. However, some of GBM patients do not respond to TMZ. O6-methylguanine-DNA-methytransferase (MGMT) remains a major cause. In a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yue, Zhang, Kai, Wang, Hao, Chen, Guangliang, Liu, Yongsheng, Li, Wen, Zhou, Youxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672402/
https://www.ncbi.nlm.nih.gov/pubmed/36407484
http://dx.doi.org/10.1016/j.bbrep.2022.101386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672402/
https://www.ncbi.nlm.nih.gov/pubmed/36407484
http://dx.doi.org/10.1016/j.bbrep.2022.101386

Ejemplares similares